Curaleaf rebuts Aurora's claims, defending its $5B acquisition offer as fair and beneficial for shareholders.

Curaleaf Holdings has released a detailed fact sheet countering Aurora Cannabis's criticisms of its $5 billion acquisition proposal. Curaleaf argues its offer includes one of the highest premiums in Canadian M&A history and highlights Aurora's poor financial performance and shareholder dilution under its current management. The company emphasizes its stronger cash flow, profitability, and growth prospects, positioning itself as a more valuable partner for Aurora shareholders. Curaleaf also addresses concerns about stock valuation, debt levels, and governance, urging Aurora to engage constructively to finalize the deal.